Drugs / Celecoxib
Celecoxib
also known as
Celebrex · Celebrex 200 · celecoxib (Celebrex) · SC-58635 · F14 · YM177 · AD-2111 · CBX · +11 more
Other / unclassified targets ABCB1, CYP2D6, GATA6, PTGS2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | CELEBREX | — | 2001-10-18 – 2018-06-28 | fda.gov ↗ |
| Filed | Japan (PMDA) | Celecox | postoperative pain, post-traumatic pain, and post-tooth extraction pain | 2011-03-30 | “it submitted a supplemental new drug application to the Ministry of Health, Labour and Welfare in Japan” astellas.com ↗ |
| Withdrawn | EU (EMA) | Onsenal | — | 2008-11-28 | europa.eu ↗ |
| Approved | EU (EMA) | Onsenal | — | 2003-10-17 | europa.eu ↗ |
| Approved | US (FDA) | CELEBREX | — | 1998-12-31 | fda.gov ↗ |
Trials 397 · started per year
today
US approved 1998
EU approved 2003
2
3
10
14
27
49
30
16
18
10
13
16
7
7
7
8
14
13
14
9
12
23
13
8
10
8
6
13
10
2
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 09 trials | ||||||
| Phase 0 | NCT06942039 | Sep 2025 → Dec 2030 expected | atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5 | C17 Council | Recruiting | No outcome recorded |
| Phase 0 | NCT04648540 | Dec 2020 → Aug 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT03820193 | Jan 2019 → Jun 2020 | substance-related disorder | Henry Ford Health System | Completed | No outcome recorded |
| Phase 0 | NCT03599453 | Jan 2019 → Sep 2020 | triple-negative breast carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 0 | NCT02362529 | Feb 2015 → Apr 2019 | major depressive disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 0 | NCT01901679 | Jul 2013 → Aug 2014 | obesity disorder | Rockefeller University | Completed | No outcome recorded |
| Phase 0 | NCT01796951 | Feb 2013 → Feb 2016 | nicotine dependence | Vanderbilt University | Completed | No outcome recorded |
| Phase 0 | NCT01881048 | Dec 2009 → Jan 2014 | female breast carcinoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 0 | NCT00585156 | Jun → Sep 2008 | — | University of Utah | Terminated | No outcome recorded |
| Phase 158 trials · 1 met primary · 2 missed | ||||||
| Phase 1 | NCT07820891 | Sep → Nov 2026 expected | — | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT07338266 | Jan → Dec 2026 expected | osteoarthritis, knee | Avidence Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT06076837 | Jan → Dec 2025 | pancreatic adenocarcinoma | HonorHealth Research Institute | Terminated | No outcome recorded |
| Phase 1 | NCT05281276 | Sep 2022 → Mar 2024 | colorectal cancer | Taipei Medical University Shuang Ho Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT05438303 | Jun → Dec 2022 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05512013 | Feb 2022 → Apr 2023 | bone resorption disease, disease of bone structure | United States Army Research Institute of Environmental Medicine | Completed | No outcome recorded |
| Phase 1 | NCT04120636 | Mar 2021 → Jun 2024 | central serous chorioretinopathy, hyalitis, macular retinal edema, occlusion of tributary of retinal vein +1 | Targeted Therapy Technologies, LLC | Unknown | No outcome recorded |
| Phase 1 | NCT04526197 | Jul → Nov 2020 | Wilson disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04490434 | Jun → Aug 2020 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT04375865 | May → Jul 2020 | — | Addpharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04090684 | Dec 2019 → Sep 2021 | amyotrophic lateral sclerosis | NeuroSense Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04081389 | Dec 2019 → May 2022 | breast carcinoma in situ, triple-negative breast carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT04041050 | Nov 2019 → Dec 2026 expected | myeloproliferative neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03876210 | Jul 2019 | arthritic joint disease | PMG Pharm Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03912428 | Jun 2019 → Jun 2024 | idiopathic inflammatory myopathy, rheumatoid arthritis | National Institute of Mental Health (NIMH) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03728179 | Jan 2019 → Oct 2023 | cancer | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1 | NCT03822520 | Jun 2017 → May 2018 | — | Samsung Medical Center | Completed | Met primary |
| Phase 1 | NCT03282838 | Jun → Aug 2017 | migraine disorder | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT02885974 | Dec 2016 → Mar 2024 | urinary bladder cancer | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02711579 | May 2016 → Apr 2017 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT06004947 | Jan → Mar 2016 | anti-neutrophil cytoplasmic antibody-associated vasculitis | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02502006 | Nov 2015 → Sep 2022 | — | University of Pennsylvania | Terminated | Mixed Stop: Enrollment |
| Phase 1 | NCT02602509 | Nov 2015 → Feb 2016 | tuberculosis | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 1 | NCT03051685 | Jul → Aug 2015 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT02502500 | Jul 2015 | — | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02131012 | Jun 2015 → Nov 2016 | — | Vanderbilt University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02401295 | May → Aug 2015 | plasma cell myeloma | University of Iowa | Completed | No outcome recorded |
| Phase 1 | NCT02115074 | Jun 2014 → Nov 2018 | glioma | Centre Oscar Lambret | Completed | No outcome recorded |
| Phase 1 | NCT02084511 | Mar → Oct 2014 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT02037165 | Jan → Apr 2014 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT02030964 | Jan 2014 → Dec 2023 | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Completed | No outcome recorded |
| Phase 1 | NCT01705106 | Aug 2012 → Feb 2016 | cancer of unknown primary site | University of Chicago | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01549743 | May → Jun 2012 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01258868 | Dec 2010 → Jun 2016 | esophageal cancer, lung cancer, mesothelioma, sarcoma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01020279 | Oct 2009 → Jan 2010 | musculoskeletal system disorder | X-pert Med GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00104767 | Jan 2009 → Oct 2014 | lung cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00729495 | Jul → Aug 2008 | — | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT00700687 | Jun → Jul 2008 | — | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT00400374 | Aug 2007 → Dec 2012 | head and neck cancer | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT00177853 | Dec 2006 | malignant pancreatic neoplasm | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 1 | NCT00296127 | Feb → Mar 2006 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00084721 | Mar → Oct 2005 | colorectal cancer, diarrheal disease | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00290680 | Mar 2005 → Jan 2009 | cancer of unknown primary site | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT00108186 | Oct 2004 → Jun 2010 | non-small cell lung carcinoma | US Department of Veterans Affairs | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00450736 | Mar 2004 → May 2009 | childhood malignant neoplasm, sarcoma | University of Miami | Completed | No outcome recorded |
| Phase 1 | NCT00088959 | Dec 2003 → Jan 2009 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00075673 | Nov 2003 → Sep 2004 | breast cancer | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00346801 | Sep 2003 → Oct 2012 | lung cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00072072 | Aug 2003 → Jan 2006 | lung cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00328432 | Jun 2003 → Dec 2005 | breast cancer | University of Kansas | Completed | No outcome recorded |
| Phase 1 | NCT00070057 | Apr 2003 → Feb 2010 | female breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00685568 | Nov 2002 → Apr 2006 | colorectal cancer, precancerous condition | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00037817 | May 2002 → Oct 2008 | esophageal cancer, non-small cell lung carcinoma, pleural mesothelioma, small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00223691 | Mar 2002 → Jan 2017 | autonomic nervous system disorder, orthostatic hypotension | Vanderbilt University | Completed | Mixed |
| Phase 1 | NCT00551005 | Dec 2001 → Feb 2012 | cancer of unknown primary site | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00551889 | Sep 2001 → Feb 2012 | cancer of unknown primary site | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00001693 | Mar 1998 → Jan 2002 | hereditary nonpolyposis colon cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/225 trials | ||||||
| Phase 1/2 | NCT03686657 | Dec 2026 → Dec 2030 | arthritic joint disease, hypertensive disorder, obesity disorder, type 2 diabetes mellitus | ARKAY Therapeutics | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT07632235 | Jul 2026 → Dec 2029 expected | intrahepatic cholangiocarcinoma | Shanghai 6th People's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05756166 | Feb 2024 → Apr 2025 | female breast carcinoma, triple-negative breast carcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05476679 | Sep 2022 → Jun 2023 | — | Raziel Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT02770378 | Nov 2016 → Oct 2018 | glioblastoma | University of Ulm | Completed | No outcome recorded |
| Phase 1/2 | NCT02054104 | Sep 2014 → Jun 2015 | melanoma, respiratory system cancer, sarcoma, thoracic cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT02151448 | Jul 2014 → Feb 2019 | malignant pancreatic neoplasm, malignant peritoneal mesothelioma, peritoneal carcinomatosis | David Bartlett | Completed | No outcome recorded |
| Phase 1/2 | NCT01545141 | Oct 2012 → Apr 2016 | colorectal carcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT01280006 | Jan → Dec 2011 | hypertensive disorder, obstructive sleep apnea syndrome, stroke disorder | University of Calgary | Completed | No outcome recorded |
| Phase 1/2 | NCT01021215 | May 2010 → Aug 2012 | nicotine dependence | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00953849 | Nov 2009 → Dec 2015 | oral cavity cancer | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 1/2 | NCT01769625 | Jan 2009 → Nov 2016 | breast cancer | Hartford Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01425476 | Jul 2008 → Nov 2016 | breast cancer | Hartford Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00970502 | Feb 2007 → Nov 2010 | larynx cancer, paranasal sinus neoplasm, pharynx cancer | Johnny Kao | Completed | No outcome recorded |
| Phase 1/2 | NCT00314262 | Oct 2006 → Nov 2012 | precancerous condition | Emory University | Completed | No outcome recorded |
| Phase 1/2 | NCT00357617 | Jun 2006 → ? | head and neck cancer | Centre Hospitalier Universitaire Vaudois | Unknown | No outcome recorded |
| Phase 1/2 | NCT00293436 | Jan 2005 → ? | liver cancer | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00159484 | Oct 2004 → Jan 2015 | colon carcinoma | University of Southern California | Completed | No outcome recorded |
| Phase 1/2 | NCT00188565 | Mar 2004 → Mar 2009 | colorectal neoplasm | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1/2 | NCT00212108 | Nov 2003 → Mar 2007 | nasopharyngeal carcinoma | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 1/2 | NCT00073866 | Jun 2003 → Dec 2004 | lung cancer | Northwestern University | Completed | No outcome recorded |
| Phase 1/2 | NCT00581971 | Sep 2002 → Dec 2007 | cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1/2 | NCT00046839 | Jul 2002 → Sep 2011 | lung cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00023660 | Aug 2001 → Jan 2005 | cervical cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00152828 | Feb 2001 → Jan 2011 | cervical carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2150 trials · 6 met primary · 15 missed | ||||||
| Phase 2 | NCT07139405 | Sep 2026 → Sep 2027 expected | type 2 diabetes mellitus | Myopharm Limited | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07809893 | Aug 2026 → Dec 2027 expected | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07597902 | Jun 2026 → Jun 2028 expected | long COVID-19 | Icahn School of Medicine at Mount Sinai | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07494565 | Mar → Dec 2026 expected | diffuse large B-cell lymphoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07174570 | Jan → Nov 2026 expected | hepatocellular carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT07150949 | Aug 2025 → Aug 2027 expected | — | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06997068 | Aug 2025 → Aug 2029 expected | hypopharyngeal carcinoma, laryngeal carcinoma, oral cavity carcinoma, oropharyngeal carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT07104266 | Aug 2025 → Aug 2028 expected | triple-negative breast carcinoma | University of Sherbrooke | Recruiting | No outcome recorded |
| Phase 2 | NCT07049185 | Jul 2025 → Mar 2027 expected | esophageal squamous cell carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06903858 | Jun 2025 → Apr 2028 expected | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Show all 150 trials opens the full record — a long page | ||||||
| Phase 2/310 trials · 1 missed | ||||||
| Phase 2/3 | NCT04860635 | Jan 2027 → Jul 2028 | — | Arthritis Innovation Corporation | Suspended | No outcome recorded |
| Phase 2/3 | NCT05509946 | Oct 2022 → Apr 2023 | — | Indonesia University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03825809 | Jan 2019 → Jan 2020 overdue | substance-related disorder | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03818932 | Jan 2019 → Jan 2020 | — | Henry Ford Health System | Completed | Mixed |
| Phase 2/3 | NCT00808743 | May 2009 → Jul 2011 | classic familial adenomatous polyposis, intestinal polyp, tumor of duodenum | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00934739 | Jun 2007 → Dec 2012 | oral cavity cancer | National Health Research Institutes, Taiwan | Terminated | No outcome recorded |
| Phase 2/3 | NCT00268476 | Jul 2005 → Mar 2026 overdue | prostate cancer | Medical Research Council | Active not recruiting | Mixed |
| Phase 2/3 | NCT00136487 | Oct 2002 → Sep 2006 | prostate cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT00027976 | Dec 2001 → Dec 2005 | precancerous condition | University of Alabama at Birmingham | Withdrawn | Missed primary |
| Phase 2/3 | NCT00006124 | Jun 2000 → Mar 2006 | bladder transitional cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 356 trials · 4 met primary · 8 missed | ||||||
| Phase 3 | NCT06863636 | Sep 2024 → Oct 2025 overdue | osteoarthritis, hip, osteoarthritis, knee | Laboratorios Silanes S.A. de C.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT06516094 | Apr 2024 → Jan 2025 | chronic pain syndrome | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT06285617 | Apr 2024 → Jan 2025 | subacute thyroiditis | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
| Phase 3 | NCT05603832 | Nov 2022 → Nov 2023 | — | Arthritis Innovation Corporation | Completed | No outcome recorded |
| Phase 3 | NCT05415397 | Sep 2022 → Jun 2026 | major depressive disorder | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 3 | NCT05362851 | Nov 2021 → Jan 2023 | osteoarthritis, knee | Yooyoung Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04429022 | Nov 2020 → May 2022 | — | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT04176419 | Jan 2020 → Jun 2021 | — | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT03974932 | Jun 2019 → Dec 2020 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03586934 | Jun 2018 → Jun 2019 | substance-related disorder | Rush University Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03062644 | Apr 2017 → Jun 2018 | — | Mundipharma Research GmbH & Co KG | Completed | Missed primary |
| Phase 3 | NCT03009019 | Dec 2016 → Nov 2017 | migraine disorder | BioDelivery Sciences International | Completed | Mixed |
| Phase 3 | NCT02979197 | Nov 2016 → Jul 2017 | hypertensive disorder | Kitov Pharma Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03059238 | Sep 2016 → Mar 2019 | liver cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02703363 | Aug 2016 → Dec 2018 | bipolar depression | Pakistan Institute of Living and Learning | Completed | Missed primary |
| Phase 3 | NCT02726659 | May 2016 → Jan 2019 | bipolar disorder, postpartum depression | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02172040 | Jun 2014 → Nov 2015 | hypertensive disorder | Kitov Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02108366 | Mar 2014 → Mar 2018 | influenza | The University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT02537925 | Jan 2014 → Dec 2016 | nasopharyngeal carcinoma | Changjie Huang | Unknown | No outcome recorded |
| Phase 3 | NCT01858571 | Oct 2013 → Jul 2016 | childhood malignant neoplasm | All India Institute of Medical Sciences | Completed | Missed primary |
| Phase 3 | NCT01150045 | Jun 2010 → Feb 2020 | colorectal cancer | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 3 | NCT01041781 | Feb 2010 → Jan 2017 | lung cancer | Alliance for Clinical Trials in Oncology | Terminated | Missed primary |
| Phase 3 | NCT00976716 | Sep → Nov 2009 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00762463 | Jul 2009 → Jun 2010 | ankylosing spondylitis | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00809354 | Feb 2009 → Oct 2010 | osteoarthritis | Pfizer | Terminated | Mixed |
| Phase 3 | NCT00549549 | Feb 2008 → Dec 2009 | gout | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01017380 | Jan 2008 → Jan 2009 | — | Prince of Songkla University | Completed | No outcome recorded |
| Phase 3 | NCT00662558 | Jan → Sep 2008 | — | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00402987 | Dec 2006 → Nov 2007 | pharyngitis | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00585312 | Sep 2006 → Oct 2013 | classic or attenuated familial adenomatous polyposis | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00295035 | Mar 2006 → Mar 2007 | colonic neoplasm | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00305643 | Feb 2006 → Oct 2008 | breast cancer, colorectal cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02429427 | Dec 2005 → Mar 2019 | female breast carcinoma | Imperial College London | Completed | Missed primary |
| Phase 3 | NCT00486460 | Jun 2005 → ? | pancreatic adenocarcinoma | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00141154 | Oct 2004 → ? | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00150280 | Oct 2004 → Jul 2005 | neuropathy, painful | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00163241 | Jun 2004 → Jan 2006 | osteoarthritis | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00092768 | Mar 2004 → Feb 2005 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092781 | Mar 2004 → Feb 2005 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00211952 | Mar 2004 → ? | non-small cell lung carcinoma | Medical University of Gdansk | Suspended | No outcome recorded |
| Phase 3 | NCT00085163 | Mar 2004 → Nov 2005 | colorectal cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00525096 | Jul 2003 → Dec 2004 | breast cancer | ARCAGY/ GINECO GROUP | Completed | No outcome recorded |
| Phase 3 | NCT00064181 | May 2003 → Jan 2005 | colorectal cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00092352 | Apr → Dec 2003 | osteoarthritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00092365 | Apr → Nov 2003 | osteoarthritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00101686 | Feb 2003 → Oct 2008 | colorectal neoplasm | Pfizer | Completed | Met primary |
| Phase 3 | NCT00648141 | Jan 2003 → Jan 2005 | ankylosing spondylitis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00050479 | Dec 2002 → Jul 2006 | macular degeneration | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 3 | NCT00137410 | Nov 2002 → Mar 2006 | osteoarthritis, knee | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00652925 | Oct 2002 → Apr 2004 | juvenile idiopathic arthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00348452 | Sep 2002 → Aug 2003 | chronic pain syndrome | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00981201 | Nov 2001 → Jul 2007 | — | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00007189 | Jan 2001 → May 2007 | Alzheimer disease | Seattle Institute for Biomedical and Clinical Research | Completed | Missed primary |
| Phase 3 | NCT00009230 | Jun 2000 → Jun 2005 | amnestic disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT00032890 | Apr 2000 → Feb 2004 | osteoarthritis | US Department of Veterans Affairs | Completed | Missed primary |
| Phase 3 | NCT00005094 | Mar 2000 → Apr 2006 | colon carcinoma, rectal cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 460 trials · 9 met primary · 4 missed | ||||||
| Phase 4 | NCT06699966 | Jun 2027 → Jun 2031 expected | major depressive disorder | Stony Brook University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07116564 | Aug 2025 → Aug 2026 overdue | — | Aga Khan University | Recruiting | No outcome recorded |
| Phase 4 | NCT07076069 | Jul 2025 → Jun 2028 expected | rotator cuff syndrome | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06671002 | Jan 2025 → Oct 2026 expected | — | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT06379425 | Mar 2024 → Jan 2027 expected | — | Northwell Health | Recruiting | No outcome recorded |
| Phase 4 | NCT06159114 | Dec 2023 → Jan 2025 | chronic prostatitis | Xintian Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT05722002 | Feb 2023 → Dec 2026 expected | neuropathy, painful | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT05288374 | Feb 2022 → Nov 2023 | — | Charles University, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT04522206 | Aug 2020 → Jun 2021 | vertebral column disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT04259333 | Mar → Dec 2020 | neuropathy, painful, substance-related disorder | Blake Raggio | Unknown | No outcome recorded |
| Phase 4 | NCT04147013 | Feb 2020 → Feb 2026 overdue | aspirin-induced respiratory disease, chronic rhinosinusitis | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04015908 | Aug 2019 → Jan 2023 | substance-related disorder | University of Utah | Completed | Met primary |
| Phase 4 | NCT03859024 | Mar 2019 → Apr 2023 | urethral stricture | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT03549611 | Aug 2018 → Jun 2019 | nephrolithiasis | Kevin J Flynn MD | Withdrawn | No outcome recorded |
| Phase 4 | NCT04814355 | Aug 2018 → Aug 2025 | major depressive disorder | Stony Brook University | Completed | No outcome recorded |
| Phase 4 | NCT03584074 | Jul 2018 → May 2019 | lumbar spinal stenosis | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03190603 | Jun 2018 | spondyloarthropathy | Armed Forces Capital Hospital, Republic of Korea | Completed | No outcome recorded |
| Phase 4 | NCT03404479 | Jan 2018 → Jan 2019 | osteoarthritis, knee | Whan-Seok Choi | Unknown | No outcome recorded |
| Phase 4 | NCT03121963 | Nov 2017 → Nov 2020 | — | University of Alabama at Birmingham | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02160301 | Nov 2017 → Dec 2019 | — | University of North Carolina, Chapel Hill | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02739035 | Apr 2016 → Dec 2022 | — | Mayo Clinic | Completed | Missed primary |
| Phase 4 | NCT02961998 | Jul 2015 → Jul 2016 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT02667730 | Jun 2015 → May 2019 | ligament disorder | Canadian Department of National Defence | Completed | No outcome recorded |
| Phase 4 | NCT02198924 | Dec 2014 → Nov 2016 | — | Peking Union Medical College Hospital | Completed | Met primary |
| Phase 4 | NCT02389465 | Aug 2014 → Jul 2022 | depressive disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT01838044 | Oct 2013 → May 2015 | neuropathy, painful | Viatris Inc. | Terminated | Missed primary Stop: Enrollment |
| Phase 4 | NCT02850211 | Sep 2011 → Nov 2015 | rotator cuff syndrome | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01479829 | Mar 2011 → Dec 2017 | bipolar depression | Loyola University | Completed | Met primary |
| Phase 4 | NCT00994461 | Nov 2009 → Apr 2010 | — | Viatris Inc. | Completed | Met primary |
| Phase 4 | NCT00894790 | Nov 2009 → Jan 2010 | — | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00807846 | Sep 2009 → Dec 2012 | juvenile idiopathic arthritis | Viatris Inc. | Completed | Missed primary |
| Phase 4 | NCT01111591 | Nov 2008 → Jun 2017 | bile duct cancer, malignant pancreatic neoplasm | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00624559 | Feb 2008 → Jan 2009 | hypertensive disorder | University of Delaware | Completed | No outcome recorded |
| Phase 4 | NCT00778193 | Oct 2007 → Mar 2008 | peptic ulcer disease | Research Associates of New York, LLP | Completed | No outcome recorded |
| Phase 4 | NCT00447759 | Jun 2007 → Aug 2015 | osteoarthritis, rheumatoid arthritis | University of Dundee | Completed | Met primary |
| Phase 4 | NCT00446797 | May 2007 → Apr 2008 | — | Viatris Inc. | Completed | Missed primary |
| Phase 4 | NCT00359151 | Nov 2006 → Jul 2007 | osteoarthritis | Viatris Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00500279 | Nov 2006 → Oct 2009 | coronary restenosis | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00346216 | Oct 2006 → Apr 2016 | rheumatoid arthritis | Viatris Inc. | Completed | Met primary |
| Phase 4 | NCT00373685 | Oct 2006 → Nov 2010 | osteoarthritis | Viatris Inc. | Completed | Met primary |
| Phase 4 | NCT00304317 | Mar 2006 → Aug 2008 | ureterolithiasis | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 4 | NCT00290901 | Mar → Dec 2006 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00141102 | Oct 2005 → May 2009 | osteoarthritis, rheumatoid arthritis | Viatris Inc. | Completed | Met primary |
| Phase 4 | NCT00137033 | Sep 2004 → Jul 2005 | peptic ulcer disease | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00194090 | Jun 2004 → Sep 2005 | osteoarthritis, knee | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00643799 | Mar 2004 → Jan 2005 | osteoarthritis, knee | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00633438 | Jan → Jun 2004 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00640627 | Dec 2003 → Sep 2004 | osteoarthritis, knee | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00638807 | Dec 2003 → Jul 2004 | osteoarthritis, knee | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00640432 | Oct 2003 → Oct 2004 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00640809 | Oct 2003 → Apr 2004 | inflammatory bowel disease | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00174317 | Aug 2003 → Feb 2005 | osteoarthritis, hip | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00565500 | Apr 2003 → Apr 2005 | ischemic disease, osteoarthritis | University of Chieti | Completed | No outcome recorded |
| Phase 4 | NCT00633386 | Feb → Aug 2003 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00630929 | Jan 2003 → Feb 2004 | osteoarthritis, knee | Viatris Inc. | Completed | Met primary |
| Phase 4 | NCT00620867 | Oct 2002 → Mar 2003 | osteoarthritis, knee | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00471341 | Jul 2002 → Dec 2004 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT00473980 | Dec 1998 → May 2007 | colorectal cancer | Göteborg University | Completed | No outcome recorded |
| Phase 4 | NCT00261586 | ? → Mar 2004 | — | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 4 | NCT00664690 | — | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Withdrawn | No outcome recorded |
| Phase not applicable29 trials · 1 missed | ||||||
| — | NCT07673549 | Aug 2026 → Dec 2027 expected | trigeminal neuralgia | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07154433 | Sep 2025 → May 2026 | osteochondritis dissecans | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| — | NCT06722534 | Feb 2025 → Jan 2029 expected | Peutz-Jeghers syndrome, intestinal polyp | Air Force Military Medical University, China | Recruiting | No outcome recorded |
| — | NCT05994287 | Jan 2021 → Jan 2022 | — | Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty | Completed | No outcome recorded |
| — | NCT03499743 | Apr → Sep 2018 | — | Cairo University | Completed | No outcome recorded |
| — | NCT03351439 | Apr 2018 → Sep 2021 | chronic pain syndrome | Western University, Canada | Completed | No outcome recorded |
| — | NCT03339544 | Dec 2017 → Dec 2018 | pulpitis | Cairo University | Unknown | No outcome recorded |
| — | NCT02790203 | Jun 2016 → Dec 2018 | ileus | Sheba Medical Center | Unknown | No outcome recorded |
| — | NCT02413203 | Mar → Nov 2015 | — | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT02255006 | May → Oct 2014 | — | Kyunghee University Medical Center | Unknown | No outcome recorded |
| — | NCT01800799 | Feb 2013 → Dec 2014 | urinary tract infection | Buddhist Tzu Chi General Hospital | Completed | No outcome recorded |
| — | NCT02779166 | Aug 2012 → Jan 2016 | — | Northwestern University | Completed | No outcome recorded |
| — | NCT01631669 | May 2012 → Jun 2015 | myositis ossificans | Walter Reed National Military Medical Center | Unknown | No outcome recorded |
| — | NCT01323595 | Jan 2011 → Dec 2012 | — | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| — | NCT01284504 | Jan → May 2011 | colon carcinoma | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01129245 | Sep 2009 → Sep 2011 | anovulation | Oregon Health and Science University | Completed | No outcome recorded |
| — | NCT00614406 | Jan → Aug 2008 | — | Oregon Health and Science University | Completed | No outcome recorded |
| — | NCT00526214 | Oct 2007 → May 2009 | intracerebral hemorrhage | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT00686140 | Jun 2006 → Dec 2007 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT00084578 | Mar 2004 → Apr 2006 | urinary bladder cancer | Fox Chase Cancer Center | Withdrawn | No outcome recorded |
| — | NCT00596219 | Dec 2003 → Oct 2006 | squamous cell carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00065559 | Apr 2003 → Dec 2004 | diabetic kidney disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Terminated | Missed primary |
| — | NCT01762891 | Mar 2003 → Jul 2006 | antiphospholipid syndrome | Hospital Universitario Pedro Ernesto | Completed | No outcome recorded |
| — | NCT00608595 | Jul 2002 → May 2004 | colorectal cancer | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00084370 | Jun 2002 → Mar 2005 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, ovarian carcinoma | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| — | NCT00653250 | Dec 2000 → Mar 2006 | lung carcinoma | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| — | NCT00065169 | Nov 2000 → Nov 2005 | Alzheimer disease | University of California, Los Angeles | Completed | No outcome recorded |
| — | NCT00093678 | — | cancer of unknown primary site, cutaneous melanoma, hypoproteinemia, hypercatabolic, lymphoma +2 | Eastern Cooperative Oncology Group | Withdrawn | No outcome recorded |
| — | NCT00533247 | — | — | Zanbilowicz, Adam, DPM MS | Unknown | No outcome recorded |
| Comparator or background therapy190 trials | ||||||
| Phase 0 | NCT03590821 Background | Dec 2027 → Jan 2028 expected | — | University of Pennsylvania | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06451783 Comparator | May 2024 → Apr 2025 | osteoarthritis, knee | Xuhui Central Hospital, Shanghai | Unknown | No outcome recorded |
| Phase 0 | NCT05852093 Comparator | Jun 2023 → Jun 2026 overdue | rotator cuff syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07632599 Background | Jul 2026 → Jun 2027 expected | ankylosing spondylitis | Eighth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07351968 Comparator | Mar → Jul 2026 | osteoarthritis, knee | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Show all 190 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2026-08-27 | Myopharm Limited | Results Myopharm Reports Preliminary Findings from TriGlytza® Type 1 Diabetes Pilot Study myopharm.com ↗
After 15 days of treatment, TriGlytza® treated animals demonstrated a statistically significant 25% reduction in non-fasting blood glucose measured four hours after morning dosing, compared with STZ-vehicle animals. |
| 2025-08-06 | Myopharm Limited | Results TriGlytza® achieves significant reduction in HbA1c % in Pre-Clinical Type 2 Diabetes myopharm.com ↗
Myopharm Limited, is pleased to announce positive significant efficacy data on the key endpoint of HbA1c % in its pre- clinical trial of TriGlytza® for the treatment of Type 2 Diabetes Mellitus (T2DM). |
| 2025-07-15 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from USFDA for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg (USRLD: Celebrex ® Capsules, 50 mg, 100 mg, 200 mg, and 400 mg). |
| 2025-04-30 | Halcygen Pharmaceuticals Limited | Regulatory Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg strides.com ↗
Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg |
| 2025-04-15 | Scilex Pharmaceuticals, Inc. | Regulatory Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Without Aura in Canada gcs-web.com ↗
today announced that it has received approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s acute treatment of migraine with or without aura in Canada. |
| 2025-01-21 | Scilex Pharmaceuticals, Inc. | Regulatory Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication gcs-web.com ↗
Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication |
| 2024-06-13 | Scilex Pharmaceuticals, Inc. | Results Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024 gcs-web.com ↗
In patients who had an insufficient response to triptans, significantly more patients in the ELYXYB®-treated arm achieved 2-hour pain freedom (the gold standard for efficacy endpoint in migraine) than placebo (33.3% vs. 14.3%, p=0.0036). |
| 2023-12-26 | Scilex Pharmaceuticals, Inc. | Regulatory Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada gcs-web.com ↗
Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada |
| 2023-09-12 | Scilex Pharmaceuticals, Inc. | Results Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV gcs-web.com ↗
In a post hoc analysis, Elyxyb demonstrated higher pain freedom rates from 60 mins through 3 hours post dose compared to ubrogepant 100 mg and Rimegepant 75 mg. |
| 2021-01-12 | NeuroSense Therapeutics Ltd. | Regulatory Neurosense Granted European Orphan Drug Designation neurosense-tx.com ↗
NeuroSense Therapeutics has gained orphan drug designation for the Ciprofloxacin Celecoxib combination pharmaceutical, PrimeC, by the European Medicine Association (EMA). |
| 2019-06-10 | Tavanta Therapeutics | Results DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor tavanta.com ↗ |
| 2016-11-13 | Pfizer | Results Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen pfizer.com ↗
The final PRECISION trial results provide statistically strong evidence that cardiovascular risk with approved doses of celecoxib is not greater than that of prescription doses of ibuprofen and naproxen. |
| 2011-03-30 | Astellas Pharma Inc | Regulatory Astellas Pharma Inc.: Submits Supplemental New Drug Application for the Selective COX-2 Inhibitor Celecox® Tablet in Japan astellas.com ↗
announced today that it submitted a supplemental new drug application to the Ministry of Health, Labour and Welfare in Japan |
| 2009-06-17 | Astellas Pharma Inc | Regulatory Announcement of Approval of Additional Indications for the Selective COX-2 Inhibitor Celecox® Tablets in Japan astellas.com ↗
“lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome, and tendinitis/tendosynovitis” were approved as additional indications for their selective COX-2 inhibitor Celecox® (generic name: celecoxib) on June 17, 2009. |
All press releases naming this drug 28 releases
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 591 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | celecoxib | “The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating...” NCT02641314 ↗559“Participants with v-akt murine thymoma viral oncogene homologue 1 (AKT1) gene mutations will receive a drug called Celecoxib, which inhibits a protein called v-akt murine...” NCT02208583 ↗ “Purpose: pharmacokinetic interactions and safety of AD-2111 and AD-2112 in healthy adult volunteers Condition or disease : Pain Intervention/treatment Drug : AD-2111(Celecoxib...” NCT04375865 ↗ “Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase...” PMID 25403311 ↗ Nov 2014 “A Six Week Double-Blind, Randomized, Multicenter Comparison Study of the Analgesic Effectiveness of Celecoxib 200 mg BID Compared to Tramadol Hydrochloride 50 mg QID in...” NCT00290901 ↗ “Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route...” NCT04562610 ↗ “PrimeC is a fixed-dose oral combination of celecoxib and ciprofloxacin designed to target ALS-related mechanisms, including neuroinflammation, iron homeostasis, and...” PMID 41837970 ↗ May 2026 “Nonsteroidal anti-inflammatory drug celecoxib (200 mg on request, up to two times daily)27 and tramadol (100 mg on request, up to 400mg daily) will be available for as-needed analgesia.” NCT06344403 ↗ “PK101, a fixed-dose combination (FDC) comprising PG201, a 12-herb extract used in OA treatment in traditional East Asian medicine, and celecoxib, a selective cyclooxygenase-2 inhibitor” PMID 39560548 ↗ Nov 2024 “Immediately after surgery, patients will receive oral acetaminophen 500 mg plus celecoxib 400 mg. Thereafter, celecoxib 200 mg BID and acetaminophen 500 mg Q6H will be administered.” NCT07154433 ↗ “Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib” NCT03563690 ↗ |
| Known as | AD-2111 | “Purpose: pharmacokinetic interactions and safety of AD-2111 and AD-2112 in healthy adult volunteers Condition or disease : Pain Intervention/treatment Drug : AD-2111(Celecoxib...” NCT04375865 ↗ |
| Known as | CBX | “using celecoxib (CBX), a cyclooxygenase 2 (COX-2) inhibitor” PMID 31630035 ↗ Oct 2019 |
| Known as | CEL | “celecoxib (CEL) (200 mg) given once daily versus placebo in knee osteoarthritis (OA).” PMID 26313454 ↗ Aug 2015 |
| Known as | Celeberex | “Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States \[US\] as Celeberex) and approved for the relief of signs and symptoms of...” NCT00424294 ↗ |
| Known as | celebra (celecoxib) | “celebra (celecoxib)” NCT01756989 ↗ |
| Known as | Celebrex | “This study will investigate the benefits of administering celecoxib (Celebrex), a selective cyclooxygenase -2 (COX-2) inhibitor, in treating osteoarthritis (OA) subjects...” NCT00359151 ↗67“This 2-part study will evaluate the effectiveness and side effects of two anti-inflammatory drugs for relieving pain and improving jaw function in patients with...” NCT00001955 ↗ “The selective cyclo-oxygenase 2 (COX-2) inhibitor, celecoxib (Celebrex, Pfizer Inc.), is being investigated as an anticancer agent in chemoprevention and adjuvant therapeutic...” NCT00596219 ↗ “Group I who will receive Tramadol 100mg (Trama SR®, Global Napi) orally 1 hour before the procedure, group II who will receive Celecoxib 200mg (Celebrex® 200, Pfizer) 1 hour...” NCT02071303 ↗ “The patients whose endometrial biopsy shows grade 2 or 3 endometrioid-type, clear cell, and papillary serous types of uterine cancers will be put on a selective COX-II...” NCT00231829 ↗ “A Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex® (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of...” NCT00640627 ↗ “A Double-Blind, Placebo-Controlled, Randomized Comparison Study of the Efficacy of Celebrex 400 mg Single Dose Pre and Celebrex 200 mg Post Ambulatory Arthroscopic Knee Surgery...” NCT00633438 ↗ “In addition, we aim to determine the effect of celecoxib (Celebrex) on tumour oxygenation, interstitial fluid pressure, COX-2 levels, prostaglandin E2 levels, angiogenesis and...” NCT00152828 ↗ “To determine if Celebrex (Celecoxib) is as effective as Toradol (Ketorolac) at controlling postoperative pain when given in addition to standard postoperative pain control regimens.” NCT03331315 ↗ “A Double-Blind, Placebo-Controlled, Randomized 24-Month Study, Assessing The Effect Of Celecoxib (Celebrex) Long Term Treatment On Hip Osteoarthritis (OA) Progression OSCARE” NCT00163241 ↗ “A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum” NCT00081224 ↗ |
| Known as | Celebrex (Registered Trademark) | “This study will determine whether the drug celecoxib (Celebrex® (Registered Trademark)) can help stabilize or improve vision in patients with age-related macular degeneration...” NCT00043680 ↗ |
| Known as | Celebrex 200 | “will receive oral Celecoxib 200 mg capsule (Celebrex®200, Pfizer, USA) once 3 hours before the colposcopic guided biopsy” NCT03464552 ↗6“Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally immediately, 12 h and 24 h after randomization.” NCT03694873 ↗ “Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide” NCT03499743 ↗ “Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.” NCT02827487 ↗ “Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to Tramadol” NCT02736019 ↗ “Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally 2 h before the procedure” NCT04505657 ↗ “one capsule of Celecoxib 200 mg (Celebrex 200, Pfizer, USA) simultaneously.” NCT05911126 ↗ |
| Known as | celecoxib (Celebrex) | “celecoxib (Celebrex®)” NCT02615574 ↗4“celecoxib (Celebrex)” NCT01769625 ↗ “celecoxib (Celebrex)” NCT01425476 ↗ “Celecoxib: Celebrex” NCT01344213 ↗ “celecoxib(celebrex)” NCT00526214 ↗ |
| Known as | Celecoxib, ATC M01AH01 | “Celecoxib, ATC M01AH01” NCT05415397 ↗ |
| Known as | Celecoxib, Celebra, Pfizer | “Celecoxib, Celebra®, Pfizer” NCT00197912 ↗ |
| Known as | CXB | “We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any.” PMID 25792707 ↗ Mar 2015 |
| Known as | Drug: Celebrex | “Drug: Celebrex” NCT02456363 ↗ |
| Known as | ELYXYB | “Celecoxib Oral Solution (ELYXYB)” PMID 34447267 ↗ Aug 2021 |
| Known as | Episcleral Celecoxib | “Drug: Episcleral Celecoxib” NCT04120636 ↗ |
| Known as | F14 | “This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14 (625 mg sustained release...” NCT05603832 ↗1“Drug: F14 (sustained release celecoxib)” NCT04860635 ↗ |
| Known as | HD042 | “the HD042 (Celecoxib) at 20uM concentration can inhibit HBV DNA, HBsAg and HBeAg by 70.87%, 88.52% and 87.55% respectively, without significant cytotoxicity.” NCT05256823 ↗ |
| Known as | SC-58635 | “Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps” NCT00141193 ↗3“Clinical Protocol For A Phase II Double-Blind, Placebo-Controlled, Randomized Study Of Celecoxib (Sc-58635) In Oral Premalignant Lesions, Investigator IND” NCT00036283 ↗ “Clinical Protocol for an Open Label Study of Celecoxib (SC-58635) on the Acute Effect of Human UV-Irradiation” NCT02090933 ↗ “Celecoxib (SC-58635)” NCT00001693 ↗ |
| Known as | YM177 | “celecoxib (YM177) 200 mg bid” NCT00141154 ↗1“Celecoxib (YM177)” NCT00976716 ↗ |
| Action | Inhibit | “Celecoxib, is in oral anti-inflammatory and analgesic agent that acts by selectively inhibiting cyclooxygenase 2 (COX-2)” NCT00001955 ↗ |
| Modality | Other / unclassified | “celecoxib, an NSAID purposefully designed to selectively inhibit COX-2” PMID 22278334 ↗ Jan 2012 |
| Route | Oral | “Celecoxib (to be provided by Searle) will be administered at 200mg p.o. BID x 12 months or 400mg p.o. BID x 12 months” NCT00001693 ↗ |
| Target | PTGS2 | “Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions” NCT00014404 ↗ |